PubRank

Deqing Pei

Author PubWeight™ 103.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 9.89
2 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
3 Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 5.37
4 Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009 4.89
5 Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004 4.21
6 Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004 4.16
7 The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013 3.43
8 Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003 2.77
9 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009 2.72
10 Agrobacterium tumefaciens-mediated transformation of maize embryos using a standard binary vector system. Plant Physiol 2002 2.43
11 Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2010 2.37
12 Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008 2.29
13 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
14 A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007 2.19
15 Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012 2.14
16 Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2011 1.88
17 Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics 2011 1.87
18 Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013 1.81
19 Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003 1.75
20 High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011 1.68
21 PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012 1.66
22 Statistical significance threshold criteria for analysis of microarray gene expression data. Stat Appl Genet Mol Biol 2004 1.62
23 Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005 1.53
24 Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007 1.52
25 Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003 1.49
26 Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013 1.45
27 Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006 1.41
28 ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012 1.39
29 In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 2008 1.37
30 Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011 1.34
31 Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 1.31
32 A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003 1.31
33 Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer 2010 1.26
34 Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol 2012 1.25
35 Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2006 1.22
36 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
37 Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014 1.10
38 Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013 1.10
39 The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008 1.04
40 Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008 1.02
41 Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the arf tumor suppressor. Invest Ophthalmol Vis Sci 2007 0.98
42 Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood 2006 0.96
43 Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005 0.94
44 Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 2014 0.89
45 Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol 2011 0.85
46 Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014 0.84
47 Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2011 0.83
48 Association of IL-1β -511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2012 0.83
49 Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 2013 0.82
50 Spinal epidural lipomatosis in children with hematologic malignancies. Ann Hematol 2011 0.82
51 Parent-controlled PCA for pain management in pediatric oncology: is it safe? J Pediatr Hematol Oncol 2012 0.81
52 Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011 0.81
53 Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatr Transplant 2011 0.77
54 Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. J Pediatr Hematol Oncol 2016 0.76
55 The Safety and Effectiveness of Patient-controlled Analgesia in Outpatient Children and Young Adults With Cancer: A Retrospective Study. J Pediatr Hematol Oncol 2015 0.75
56 Safety and Benefits of Bronchoalveolar Lavage and Lung Biopsy in the Management of Pulmonary Infiltrates in Children With Leukemia. J Pediatr Hematol Oncol 2016 0.75